Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …

Background Molnupiravir is an essential oral antiviral agent against coronavirus disease
2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients …

Background: Molnupiravir is approved for the treatment of adult patients with mild to
moderate COVID-19. The main goal of the treatment is to reduce hospitalization and …

Background. Recently, different therapeutic lines have been tried in the initial stage of the
disease of COVID-19, including remdesivir and molnupiravir. There is scarce evidence on …

Department of Nephrology, Cliniques Universitaires Saint-Luc, Av. Hippocrate 10, Brussels
1200, Belgium. E-mail: laura. labriola@ uclouvain. be ORCID: https://orcid. org/0000-0003 …

Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug
against SARS-CoV-2 available to us, in the treatment of patients with COVID-19. Materials …

Aims The aim of this study was to evaluate the safety profile of molnupiravir in COVID‐19
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Introduction In the present study, the efficacy of sotrovimab and molnupiravir in dialysis
patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …